Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Advances in Ovarian tumor Therapy Made at LIMR

Abstract:
Cancer Research paper shows Nanoparticle Delivery System Slowed Ovarian Tumor Growth

Advances in Ovarian tumor Therapy Made at LIMR

Wynnewood, PA | Posted on September 4th, 2009

Ovarian cancer is the fifth leading cause of cancer-related death in women and remains the leading cause of cancer death from gynecologic cancers. Currently, there is no effective therapy for patients with advanced ovarian cancer. Dr. Janet Sawicki, Professor at the Lankenau Institute for Medical Research (LIMR), along with its collaborating institution, the Massachusetts Institute of Technology (MIT), published a paper in Cancer Research whose findings suggest a potential new therapy to treat advanced stage ovarian cancer. Dr. Sawicki and her colleagues conducted preclinical tests using three different animal models to evaluate the therapeutic efficacy of using nanoparticles to deliver a diphtheria toxin suicide gene. DNA sequences, called promoters, were used to target production of the toxin protein to tumor cells. Nanoparticles were injected directly into tumors or injected into the peritoneal cavity where most of the tumors are located.

Treatment with the nanotherapy reduced tumor mass and prolonged lifespan as compared to the
control group. It also suppressed tumor growth better than two commonly used chemotherapeutic drugs, cisplatin and paclitaxel. The researchers observed very little non-specific toxicity in normal, healthy tissues.

"Unlike chemotherapy, which can destroy both cancer and healthy cells and lead to many adverse effects, this new therapy specifically targets cancer cells and leaves the healthy cells alone," stated Dr. Sawicki. "Our hope is to begin doing clinical trials in patients in the next 18 to 24 months and then potentially tailor this therapy to treat different solid tumor types including pancreatic, prostate, and cervical cancers."

A resident of Newtown Square, PA, Dr. Sawicki joined the LIMR staff in 1990 after serving as an Assistant Professor at the Wistar Institute. She received her Ph.D. in Genetics from Cornell University and her B.A. in Biology from the University of Delaware. Dr. Sawicki also completed postdoctoral work at Yale University and the University of California, San Francisco. She currently serves as an Associate Professor in the Kimmel Cancer Center at Thomas Jefferson University. Her ovarian cancer research is funded by the NIH, the Department of Defense, the Sandy Rollman Foundation, WAWA, the Teal Ribbon Ovarian Cancer Foundation, and the Kaleidoscope of Hope Foundation.

####

About Lankenau Institute for Medical Research
Founded in 1927, the Lankenau Institute for Medical Research (LIMR) is an independent, nonprofit biomedical research center located in suburban Philadelphia on the campus of the Lankenau Hospital. As part of the Main Line Health System, LIMR is one of the few freestanding, hospital-associated medical research centers in the nation. The faculty and staff at the Institute are dedicated to advancing an understanding of the causes of cancer and heart disease. They use this information to help improve diagnosis and treatment of these diseases as well as find ways to prevent them. They are also committed to extending the boundaries of human health and well-being through technology transfer and education directed at the scientific, clinical, business and lay public communities.

About Cancer Research

Cancer Research is published twice a month, one volume/year, by the American Association for Cancer Research, Inc. It publishes significant, original studies in all areas of basic, clinical, translational, epidemiological, and prevention research devoted to the study of cancer and cancer-related biomedical sciences. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit are accepted for publication.

About David H. Koch Institute for Integrative Cancer Research at MIT

Launched by MIT in 2008, the David H. Koch Institute for Integrative Cancer Research (KI) both transforms and transcends the Center for Cancer Research (CCR). CCR was founded in 1974 by Nobel Laureate and MIT Professor Salvador Luria, CCR has made enormous contributions to the field of cancer research. The Koch is one of only seven National Cancer Institute-designated basic research centers in the US and is comprised of faculty that have earned the most prestigious national and international science honors including the Nobel Prize and the National Medal of Science. For more information visit: web.mit.edu/ki/index.html.

For more information, please click here

Contacts:
Tava Shanchuk
(610) 645-3429

Copyright © Lankenau Institute for Medical Research

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

SouthWest NanoTechnologies Introduces AgeNT Transparent Conductor System at SID Display Week, Booth #543 May 28th, 2015

New technique speeds nanoMRI imaging: Multiplexing technique for nanoscale magnetic resonance imaging developed by researchers in Switzerland cuts normal scan time from two weeks to two days May 28th, 2015

Squeezed quantum cats May 28th, 2015

New chip makes testing for antibiotic-resistant bacteria faster, easier: Researchers at the University of Toronto design diagnostic chip to reduce testing time from days to one hour, allowing doctors to pick the right antibiotic the first time May 28th, 2015

Possible Futures

Global Nano-Enabled Packaging Market For Food and Beverages Will Reach $15.0 billion in 2020 May 26th, 2015

Simulations predict flat liquid May 21st, 2015

Nature inspires first artificial molecular pump: Simple design mimics pumping mechanism of life-sustaining proteins found in living cells May 19th, 2015

NNCO and Museum of Science Fiction to Collaborate on Nanotechnology and 3D Printing Panels at Awesome Con May 19th, 2015

Nanomedicine

New chip makes testing for antibiotic-resistant bacteria faster, easier: Researchers at the University of Toronto design diagnostic chip to reduce testing time from days to one hour, allowing doctors to pick the right antibiotic the first time May 28th, 2015

New electronic stent could provide feedback and therapy then dissolve May 27th, 2015

Seeing the action: UCSB researchers develop a novel device to image the minute forces and actions involved in cell membrane hemifusion May 27th, 2015

Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015

Announcements

Chemists discover key reaction mechanism behind the highly touted sodium-oxygen battery May 28th, 2015

New technique speeds nanoMRI imaging: Multiplexing technique for nanoscale magnetic resonance imaging developed by researchers in Switzerland cuts normal scan time from two weeks to two days May 28th, 2015

Squeezed quantum cats May 28th, 2015

New chip makes testing for antibiotic-resistant bacteria faster, easier: Researchers at the University of Toronto design diagnostic chip to reduce testing time from days to one hour, allowing doctors to pick the right antibiotic the first time May 28th, 2015

Nanobiotechnology

New technique speeds nanoMRI imaging: Multiplexing technique for nanoscale magnetic resonance imaging developed by researchers in Switzerland cuts normal scan time from two weeks to two days May 28th, 2015

Seeing the action: UCSB researchers develop a novel device to image the minute forces and actions involved in cell membrane hemifusion May 27th, 2015

Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015

Who needs water to assemble DNA? Non-aqueous solvent supports DNA nanotechnology May 27th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project